Source: Clinical Epigenetics. Unidades: IME, FCF, IQ
Subjects: GENOMAS, MELANOMA, BIOINFORMÁTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIUS, Flávia Eichemberger et al. Genome-wide promoter methylation profling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival. Clinical Epigenetics, v. 14, n. artigo 68, p. 1-20, 2022Tradução . . Disponível em: https://doi.org/10.1186/s13148-022-01291-x. Acesso em: 25 ago. 2024.APA
Rius, F. E., Papaiz, D. D. 'A., Azevedo, H., Ayub, A. L. P., Pessoa, D. de O., Oliveira, T. F. de, et al. (2022). Genome-wide promoter methylation profling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival. Clinical Epigenetics, 14( artigo 68), 1-20. doi:10.1186/s13148-022-01291-xNLM
Rius FE, Papaiz DD'A, Azevedo H, Ayub ALP, Pessoa D de O, Oliveira TF de, Loureiro AP de M, Andrade F, Fujita A, Reis EM, Mason CE, Jasiulionis MG. Genome-wide promoter methylation profling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival [Internet]. Clinical Epigenetics. 2022 ; 14( artigo 68): 1-20.[citado 2024 ago. 25 ] Available from: https://doi.org/10.1186/s13148-022-01291-xVancouver
Rius FE, Papaiz DD'A, Azevedo H, Ayub ALP, Pessoa D de O, Oliveira TF de, Loureiro AP de M, Andrade F, Fujita A, Reis EM, Mason CE, Jasiulionis MG. Genome-wide promoter methylation profling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival [Internet]. Clinical Epigenetics. 2022 ; 14( artigo 68): 1-20.[citado 2024 ago. 25 ] Available from: https://doi.org/10.1186/s13148-022-01291-x